Basic Information
| LncRNA/CircRNA Name | lncRNA-HAL |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin, Paclitaxel, Tamoxifen, Doxorubicin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, in vitro knockdown, RNAi |
| Sample | Multicellular Tumor Spheroids culture cell |
| Expression Pattern | up-regulated |
| Function Description | The results obtained in the present work suggest that the function of lncRNA -HAL is associated with quiescent stem cell populations, which in turn is relevant due to its implications in cancer cell survival and resistance against treatment in vivo . Altogether, our data highlights a new lncRNA whose expression is regulated by the tumor microenvironment and associated to stemness in breast cancer. |
| Pubmed ID | 31401107 |
| Year | 2019 |
| Title | Microenvironment-regulated lncRNA-HAL is able to promote stemness in breast cancer cells |
External Links
| Links for lncRNA-HAL | GenBank HGNC NONCODE |
| Links for Triple negative breast cancer | OMIM COSMIC |